STSanne Marie Thysen

Sanne Marie Thysen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanne Marie Thysen has a total of 234 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigating Potential Adverse Drug Reactions of Lisdexamfetamine Using Sequence Symmetry Analysis

    by Thomas Leth Jensen, Sanne Møller Thysen, Espen Jimenez‐Solem, Anders Jørgensen, Camilla Bjørn Jensen, Hans Kristian Råket, Merete Osler, Mads Nielsen, Lars Christian Lund

    The prevalence of ADHD is increasing rapidly, and lisdexamfetamine is increasingly popular, but few studies investigate its safety. We performed a sequence symmetry analysis (SSA) using Danish register data to identify potential ADRs associated with lisdexamfetamine in 2013–2023. Outcomes were incident prescriptions or incident discharge diagnoses. We calculated trend‐adjusted sequence ratios (SR) with 95% confidence intervals (CI). We additionally performed two comparator SSAs for the same outcomes following incident use of stimulants (methylphenidate and dexamfetamine) or non‐stimulants (guanfacine and atomoxetine). This study is reported according to RECORD‐PE guidelines. We included 48 740 incident lisdexamfetamine users with a median age of 24 years (IQR 16–35). SRs were calculated for 1426 exposure–diagnosis and 1337 exposure–prescription pairs. The 50 highest SRs from each category were evaluated. Among these, 28 exposure–outcome combinations had a 95% CI lower bound above 1. Of the 100 outcomes, 33 were considered known ADRs, while 60 were previously unknown. Two outcomes indicating increased urinary symptoms were identified (‘hematuria’, SR: 1.88 [95% CI: 1.25; 2.85] and ‘other urinary symptoms’, SR: 1.63 [1.20; 2.23]). We also identified serious gastrointestinal outcomes as a potential safety alert. Further investigation into these symptoms as potential ADRs is warranted.

  • Open Access

    Acute symptoms and subsequent post-acute symptoms following COVID-19 vaccination: A Danish population-based study

    by Christina Bisgaard Jensen, Andrea Skovgaard Sørensen, Kristoffer Torp Hansen, Stefan Nygaard Hansen, Marie Josiasen, Asta Holberg Le Marc, Sofie Ahlgreen Gram, Caroline Lunne Fahnøe, Henrik Nielsen, Charlotte Ulrikka Rask, et al.


  • Open Access

    Fatigue, neurological, and cognitive symptoms after COVID-19 - a nationwide matched cohort study in Denmark

    by Kristoffer Torp Hansen, Christina Bisgaard Jensen, Rikke Overgaard, Stefan Nygaard Hansen, Charlotte Ulrikka Rask, Per Fink, Henrik Nielsen, Thomas Meinertz Dantoft, Torben Jørgensen, Sanne Møller Thysen, et al.

    To investigate if COVID-19 increases the odds of fatigue, headache, dizziness, concentration difficulties, and memory impairment as well as at least three of these symptoms, at 12 weeks after COVID-19. Additionally, we investigated whether symptoms were influenced by severity of COVID-19, sex, and pre-infection COVID-19 vaccination. This study utilised data from the DanishBiCoVac cohort and national registers. The BiCoVac cohort collected information about symptoms through four questionaries distributed between May 2021 and May 2022. Participants with COVID-19 were matched to participants without COVID-19.Three matching samples were created according to time since COVID-19. Logistic regression was performed for the association between COVID-19 and each outcome. Participants with COVID-19 within 0-4 weeks had higher odds of reporting all outcomes compared to participants without COVID-19. Between 4 and 12 weeks after COVID-19, the odds of symptoms were also higher, although attenuated. After 12 weeks, participants with COVID-19 also had higher odds of symptoms except for concentration difficulties compared to those without COVID-19. Odds for symptoms were highest for participants reporting severe infection. Prior COVID-19 vaccination might weaken the association while no clear modification was found for sex. Participants with COVID-19 had higher odds of all outcomes, especially within the first 4 weeks. After 12 weeks, the ORs were attenuated but still indicated an association for all outcomes except concentration difficulties. Individuals vaccinated against COVID-19 tended to report fewer symptoms after COVID-19. Participants with severe COVID-19 had the highest odds of symptoms.

  • Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study

    by Christina Bisgaard Jensen, Kristoffer Torp Hansen, Bodil Hammer Bech, Stefan Nygaard Hansen, Henrik Nielsen, Charlotte Ulrikka Rask, Per Fink, Thomas Meinertz Dantoft, Torben Jørgensen, Jeremy A Labrecque, et al.

    Background: Post-acute non-specific symptoms such as headaches, muscular pain, and fatigue are frequently reported following COVID-19 vaccination, raising concerns about adverse events. As vaccine-hesitant individuals may be more likely to experience symptoms of vaccines, this study investigates whether COVID-19 vaccination increases the odds of post-acute non-specific symptoms, stratified by COVID-19 vaccine hesitancy. Methods: This longitudinal study uses repeated measurements from the BiCoVac cohort—a random sample of 913 116 Danish citizens aged 16–65 years. Data were collected through national registers and questionnaires (May 2021–June 2022). Non-specific symptoms were identified by using the 25-item Bodily Distress Syndrome checklist and analysed by using logistic and linear regression models comparing vaccinated and unvaccinated individuals. Models were fitted with robust standard errors and inverse probability of selection weights. Results: A total of 132 776 observations were collected from 61 316 COVID-19 vaccine-unconcerned individuals, 52 325 observations from 25 272 COVID-19 vaccine-sceptical individuals, and 10 242 observations from 5064 COVID-19 vaccine-concerned individuals. Among the vaccine-unconcerned individuals, those vaccinated had lower odds of most symptoms compared with unvaccinated individuals >4 weeks post-vaccination [e.g. muscular pain: odds ratio (OR) = 0.56, 95% confidence interval (CI): 0.47–0.68]. A similar tendency was found for vaccine-sceptical individuals, although with attenuated estimates. Conversely, among vaccine-concerned individuals, we observed a tendency for higher odds of most symptoms >4 weeks post-vaccination compared with unvaccinated individuals (e.g. muscular pain: OR = 1.23, 95% CI: 0.91–1.67). Conclusion: For most individuals aged 16–65 years, we found no evidence of post-acute symptoms after COVID-19 vaccination. Vaccinated vaccine-concerned individuals were, however, more likely to report most symptoms, potentially due to reporting bias or nocebo effects.


  • Open Access

    Displacements in reported date of birth and differences in age at death in surveys of child mortality: a record linkage study in Guinea-Bissau

    by Andreas Møller Jensen, Sanne Marie Thysen, Justiniano Sebastião Durga Martins, Didier Abdel Fernandes, Amabelia Rodrigues, Stéphane Helleringer, Ane Bærent Fisker

    Child mortality data in low- and middle-income countries are often derived from survey data prone to imprecision due to recall. Such imprecisions can affect the accuracy of date of birth (DOB) and age at death (AAD). Bandim Health Project runs two Health and Demographic Surveillance Systems (HDSSs) collecting prospective information on pregnancies, births, and deaths in Guinea-Bissau. In a survey, HDSS resident women were interviewed on their births and survival status of their children born within 5 years prior to the interview. We matched child records in the survey data to their corresponding records in the HDSS data based on sex, name, birth order, twinning status, and sibling names. We compared the risk and magnitude of displacement in DOB and AAD in regression models to identify risk factors for displacement. A total of 7679 out of 9960 survey-reported live births (78%) were matched to HDSS-reported births. Displacement in month or year of birth was observed for 9%, with a median displacement of 30 days backwards. Child death was associated with larger risk of displacement in DOB (adjusted risk ratio: 5.16 (95% confidence interval: 4.44–5.99)) and greater magnitude of displacement. A longer recall period was also associated with a greater risk of displacement. Among 339 children who had died, 68% had a discrepancy in AAD with 34% of these exceeding 1 week. Discrepancies were common and more likely for longer recall periods and children who had died. Hence, the interpretation of temporal mortality patterns from survey data may be compromised.

  • Open Access

    Cohort profile: The BiCoVac cohort - a nationwide Danish cohort to assess short and long-term symptoms following COVID-19 vaccination

    by Christina Bisgaard Jensen, Kristoffer Torp Hansen, Casper Mailund Nielsen, Stefan Nygaard Hansen, Henrik Nielsen, Charlotte Ulrikka Rask, Per Fink, Thomas Meinertz Dantoft, Torben Jørgensen, Bodil Hammer Bech, et al.

    BiCoVac is a population-based Danish cohort aiming to examine whether Coronavirus disease 2019 (COVID-19) vaccines are associated with non-specific symptoms beyond the specific protection of COVID-19. Data were collected by four questionnaire surveys between May 2021 and July 2022 and the questionnaire distribution was aligned with the Danish COVID-19 vaccination program. All surveys collected self-reported information on symptoms (e.g., headache, nausea, and fatigue). The baseline survey additionally gathered information on lifestyle and health. Survey data were combined with data from the Danish registers including information on COVID-19 vaccination and COVID-19 test results. A total of 911,613 (25% of all Danish citizens aged 16 to 65) were randomly sampled for the cohort and 252,401 initiated the baseline questionnaire. Of these, 59% (n = 149,070) participated in the 1st follow-up, 43% (n = 107,655) in the 2nd follow-up, and 25% (n = 63,737) in the 3rd follow-up. Women and individuals above 40 years of age were more likely to participate. Among vaccinated respondents, 25–38% reported moderate to severe immediate symptoms following COVID-19 vaccination, varying by vaccine doses. Females, younger individuals, and those with prior COVID-19 reported more immediate symptoms. Results of potential non-specific symptoms following COVID-19 vaccination did not reveal higher risk of involuntary movements among vaccinated individuals compared to unvaccinated individuals. Currently (December 2024), we are further investigating the effects of COVID-19 vaccines on other non-specific symptoms and exploring whether specific characteristics render some individuals more susceptible to report non-specific symptoms. In addition, long-term symptoms following COVID-19 are being investigated.


  • Open Access

    Does health anxiety and vaccine concern predict self-reported adverse events following COVID-19 vaccination?–A Danish national cohort study

    by Kristoffer Torp Hansen, Fiona Kusk Povlsen, Bodil Hammer Bech, Stefan Nygaard Hansen, Charlotte Ulrikka Rask, Per Fink, Henrik Nielsen, Thomas Meinertz Dantoft, Sanne Marie Thysen, Dorte Rytter


  • Open Access

    Contradictory mortality results in early 2-dose measles vaccine trials: interactions with oral polio vaccine may explain differences

    by Sebastian Nielsen, Ane B. Fisker, Ali Sie, Olaf Müller, Eric Nebie, Heiko Becher, Fiona van der Klis, Sofie Biering-Sørensen, Stine Byberg, Sanne M. Thysen, et al.


  • Open Access

    Can earlier BCG-Japan and OPV vaccination reduce early infant mortality? A cluster-randomised trial in Guinea-Bissau

    by Sanne Marie Thysen, Igualdino da Silva Borges, Jailson Martins, Alexander Dahl Stjernholm, Jesper Sloth Hansen, Leontino Manuel Vieira da Silva, Justiniano Sebastião Durga Martins, Aksel Jensen, Amabelia Rodrigues, Peter Aaby, et al.

    Objective To assess the effect of providing BCG and oral polio vaccine (OPV) at an early home visit after delivery. Design Cluster-randomised trial, randomising 92 geographically defined clusters 1:1 to intervention/control arms. Setting Bandim Health Project Health and Demographic Surveillance System, Guinea-Bissau. Participants 2226 newborns enrolled between July 2016 and August 2019. Interventions In both arms, newborns received a home visit within 72 hours after birth. In intervention clusters (n=46), BCG and OPV were provided at the home visit. Main outcome measure Rates of non-accidental mortality were compared in Cox proportional hazards models from (last of) day 1 or enrolment, until (first of) day 60 or registration of non-trial vaccines. Results A total of 35 deaths (intervention: 7, control: 28) were registered during the trial. Providing BCG and OPV reduced non-accidental early infant mortality by 59% (8–82%). The intervention also reduced non-accidental hospital admissions. The intervention had little impact on growth and BCG scarring and tended to increase the risk of consultations. Conclusions The trial was stopped early due to lower-than-expected enrolment and event rates when 33% of the planned number of newborns had been enrolled. Despite the small size of the trial, the results support that early BCG and OPV vaccinations are beneficial and reduce early child mortality and morbidity. Trial registration number ClinicalTrials.gov Registry (NCT02504203).


  • Open Access

    Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents A Systematic Review and Meta-Analysis

    by Stine S. Hoffmann, Sebastian Nielsen, Sanne M. Thysen, Ram Duriseti, Christine S. Benn

    Importance Phase 3 randomized controlled trials (RCTs) of mRNA COVID-19 vaccines in children and adolescents showed efficacy in preventing COVID-19 infections. Vaccines may have non-specific effects; this is not assessed within the current regulatory framework. Objective Conduct a systematic review and meta-analysis of the phase 3 trials to assess overall and non-specific health effects of the mRNA COVID-19 vaccines in children. Data Sources PubMed, Embase, Clinical Trials, Web of Science, and regulatory websites were searched for RCTs of mRNA vaccines. The latest trial data was included. Study Selection All RCTs conducted with mRNA vaccines BNT162b2 and mRNA-1237 in children and adolescents below 18 years of age, with placebo, adjuvant, or other vaccines as controls. Two authors independently screened 1199 studies, six were included in the analysis. Data Extraction and Synthesis Data on serious adverse events (SAEs) and severe adverse events (AEs) as well as organ-specific diseases was extracted following the PRISMA reporting guideline, with a focus on non-specific infectious events. Risk Ratios (RRs) comparing vaccine and placebo cohorts were calculated separately for each vaccine and combined in Mantel-Haenszel estimates. Main Outcomes and Measures The primary outcome was SAEs, overall and infectious. Secondary outcomes were severe AEs and lower respiratory tract infection (LRTI) including RSV. Results The analyses included 25,549 individuals (17,538 mRNA vaccine recipients and 8,011 placebo recipients). The risk of SAEs was similar for vaccine and placebo recipients. Both mRNA vaccines were associated with increased risk of severe AEs in older children. In a combined analysis, the RR was 3.77 (1.56-9.13[0.4% vs 0.1% in vaccine vs placebo recipients]) in above 5 year-olds, and 0.82 (0.53-1.29)[0.8% vs 0.9%])in younger children (p=0.003 for same effect in older and younger children). In the younger children, mRNA vaccines were associated with higher risk of LRTI (RR=3.03 (1.29-7.09)[0.6% vs 0.2%]). Conclusions and Relevance mRNA vaccines did not increase the risk of SAEs but were associated with an increased risk of severe AEs in older children, and an increased risk of LRTI in the young. Further research into the overall and non-specific health effects of mRNA vaccines is warranted. Question What is the overall health effect of mRNA COVID-19 vaccines in children? Findings In this systematic review and meta-analysis of phase 3 trials, mRNA vaccine vs. placebo was not associated with increased risk of serious adverse events. The mRNA vaccines were associated with higher risk of severe adverse events in children aged 5 years and older. In children younger than 5 years, mRNA vaccines were associated with a 3-fold higher risk of lower respiratory tract infections. Meaning The results suggest that mRNA vaccines are associated with increased risk of severe adverse events and increased risk of LRTI. Given the low risk of severe COVID-19 infection in children, it is not clear that the benefits of COVID-19 vaccines in children outweigh the harms.